van der Plas, Mariena J. A.
Bhongir, Ravi K. V.
Kjellström, Sven
Siller, Helena
Kasetty, Gopinath
Mörgelin, Matthias
Schmidtchen, Artur
Article History
Received: 29 January 2016
Accepted: 8 April 2016
First Online: 16 May 2016
Competing interests
: Dr Schmidtchen is a founder of in2cure AB, a company developing anti-inflammatory peptides of thrombin for therapeutic applications. The other authors declare no competing financial interests.